%20--%3e%3csvg%20width='63.297821mm'%20height='39.29665mm'%20viewBox='0%200%2063.297821%2039.29665'%20version='1.1'%20id='svg8765'%20inkscape:version='1.1%20(c4e8f9ed74,%202021-05-24)'%20sodipodi:docname='OBALogoSingle2.svg'%20xmlns:inkscape='http://www.inkscape.org/namespaces/inkscape'%20xmlns:sodipodi='http://sodipodi.sourceforge.net/DTD/sodipodi-0.dtd'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:svg='http://www.w3.org/2000/svg'%3e%3csodipodi:namedview%20id='namedview8767'%20pagecolor='%23ffffff'%20bordercolor='%23666666'%20borderopacity='1.0'%20inkscape:pageshadow='2'%20inkscape:pageopacity='0.0'%20inkscape:pagecheckerboard='0'%20inkscape:document-units='mm'%20showgrid='false'%20fit-margin-top='0'%20fit-margin-left='0'%20fit-margin-right='0'%20fit-margin-bottom='0'%20inkscape:zoom='1.1759259'%20inkscape:cx='179.85827'%20inkscape:cy='102.04724'%20inkscape:window-width='1920'%20inkscape:window-height='972'%20inkscape:window-x='0'%20inkscape:window-y='27'%20inkscape:window-maximized='1'%20inkscape:current-layer='layer1'%20/%3e%3cdefs%20id='defs8762'%20/%3e%3cg%20inkscape:label='Layer%201'%20inkscape:groupmode='layer'%20id='layer1'%20transform='translate(-31.351095,-50.101677)'%3e%3cpath%20style='fill:none;stroke:%233584e4;stroke-width:3.965;stroke-linecap:square;stroke-linejoin:round;stroke-miterlimit:4;stroke-dasharray:none;stroke-opacity:1'%20d='m%2077.07508,77.78787%2014.84134,8.87817%20V%2052.83397%20L%2034.08359,86.5521%20V%2053.69366%20l%2015.27351,9.31107'%20id='path8388'%20sodipodi:nodetypes='cccccc'%20/%3e%3c/g%3e%3c/svg%3e)
Market Performance
Stock returned +10.0% over the past year, broadly in line with market conditions.What is Wuhan General Gr Chn?
, a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research.
WUHN · Verdict
Limited reward · elevated risk
WUHN stands out on volatility and balance sheet, but watch the profitability signal.
Based on 88% data coverage
WUHN · Verdict
What’s working & what to watch
Strengths 3
- Volatility75/100
Above average
- Balance sheet69/100
Current ratio 3.18
- Valuation67/100
Above average
Watchouts 3
- Profitability9/100
-12087% net margin · -9% ROE
- Cash flow12/100
-11715% free-cash-flow margin
- Growth15/100
Rev -94.4% CAGR · earnings -45.5%
Model-based scoring. For information only — not financial advice.
What is Wuhan General Gr Chn?
, a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 11.03K.
Financial Highlights
Investment Breakdown
Analysis
Reward: Low (30)The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.